Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas
Open Access
- 31 January 2014
- journal article
- Published by Springer Nature in Clinical Sarcoma Research
- Vol. 4 (1) , 2
Abstract
Serum protein acidic and rich in cysteine (SPARC) is a matricellular secreted glycoprotein that performs several cellular functions and has been implicated in tumorigenesis in a variety of tumor types. The chemotherapeutic agent nanoparticle albumin-encapsulated (NAB)-paclitaxel has been postulated to exploit SPARC expression to target neoplastic cells. SPARC’s role, and potentially the role of NAB-paclitaxel, in the highly heterogeneous class of soft-tissue sarcomas (STS) has not been investigated. Our objective was to explore the pattern of SPARC expression and its prognostic significance in STS.Keywords
This publication has 26 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Multidisciplinary Management of Soft Tissue SarcomaThe Scientific World Journal, 2013
- Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancerExpert Opinion on Pharmacotherapy, 2012
- Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcomaJournal of Orthopaedic Science, 2010
- Pathology of soft‐tissue tumors: Daily diagnosis, molecular cytogenetics and experimental approachPathology International, 2009
- A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing RegimensThe Oncologist, 2008
- Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcomaCancer, 2008
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Expression of mTOR signaling pathway markers in prostate cancer progressionThe Prostate, 2006
- Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over TimeJournal of Clinical Oncology, 2003